Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma

por Huang, Yufan, You, Maojin, Wu, Qundan, Chen, Ruijia
Publicado 2023

Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer

por You, Maojin, Chen, Ruijia, Wu, Qingfeng, Zhu, Wei, He, Ying, Huang, Yufan
Publicado 2022

Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer

por You, Maojin, Zeng, Xiaoling, Zhang, Jinrong, Huang, Yufan, Zhang, Yalan, Cai, Zhongjie, Hu, Yingying
Publicado 2023

Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma

por He, Ying, Lin, Wangchun, Cai, Zhongjie, Huang, Yufan, You, Maojin, Lei, Meisheng, Chen, Ruijia
Publicado 2023

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma

por You, Maojin, Huang, Yufan, Cai, Zhongjie, Wu, Qingfeng, Zhu, Wei, He, Ying, Chen, Ruijia
Publicado 2022

Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers

por Chen, Ruijia, Zhang, Yalan, Lin, Kongying, Huang, Defu, You, MaoJin, Lai, Yanjin, Wang, Jinye, Hu, Yingying, Li, Na
Publicado 2022